Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin

被引:25
作者
Schulten, R. [1 ]
Novak, B. [1 ]
Schmitz, B. [2 ]
Luebbert, H. [1 ,2 ]
机构
[1] Ruhr Univ Bochum, Dept Anim Physiol, D-44780 Bochum, Germany
[2] Biofrontera Biosci GmbH, D-51377 Leverkusen, Germany
关键词
Delta-aminolevulinic acid; Methylaminolevulinic acid; Photodynamic therapy; Protoporphyrin IX; GABA transporters (GAT); Amino acid transporters; Keratinocytes; DELTA-AMINOLEVULINIC-ACID; PHOTODYNAMIC THERAPY; PROTOPORPHYRIN-IX; ACTINIC KERATOSIS; BF-200; ALA; TRANSPORT; MULTICENTER; CELLS; PHARMACOLOGY; DERIVATIVES;
D O I
10.1007/s00210-012-0777-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Photodynamic therapy is widely used in the treatment of superficial skin cancers. 5-Aminolevulinic acid (ALA) and its methylated form, methyl-ALA (MAL), are frequently used as precursors to photosensitizing substances. Nevertheless, the mechanism of the uptake of ALA and MAL in keratinocytes and of their skin penetration is still controversial. Since both compounds are not sufficiently lipophilic to penetrate through lipid membranes, they must employ specific uptake systems which may vary between different cell types. Here, we studied ALA and MAL uptake in keratinocyte cell lines originating from healthy cells (CCD 1106 KERTr cells) or keratinocyte tumors (A431 cells). ALA uptake resulted in faster protoporphyrin IX (PpIX) production than MAL uptake. A pharmacological characterization of the uptake systems revealed that PpIX formation was most efficiently reduced with GABA transporter (GAT) substrates. GABA, beta-alanine, and (S)-SNAP-5114 reduced ALA uptake and, to a lesser extent, MAL uptake in the cell lines. The pharmacology of these compounds indicates that ALA and MAL are taken up by normal and pathological keratinocytes via GAT-3. Furthermore, the amino acids arginine, cysteine, and histidine also inhibited the uptake of ALA, and even more so MAL, suggestive of an additional involvement of amino acid transporters. To show that PpIX formation in vivo is restricted to the application site, which has been questioned for ALA in one other report, we applied clinically used ALA and MAL formulations to the skin of nude mice. Contrary to the results of these previous authors, the resulting PpIX fluorescence increased over time and was restricted to the application site for both preparations.
引用
收藏
页码:969 / 979
页数:11
相关论文
共 52 条
[1]   Photodynamic Therapy of Cancer: An Update [J].
Agostinis, Patrizia ;
Berg, Kristian ;
Cengel, Keith A. ;
Foster, Thomas H. ;
Girotti, Albert W. ;
Gollnick, Sandra O. ;
Hahn, Stephen M. ;
Hamblin, Michael R. ;
Juzeniene, Asta ;
Kessel, David ;
Korbelik, Mladen ;
Moan, Johan ;
Mroz, Pawel ;
Nowis, Dominika ;
Piette, Jacques ;
Wilson, Brian C. ;
Golab, Jakub .
CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) :250-281
[2]  
Babilas P, 2010, GIORN ITAL DERMAT V, V145, P613
[3]   Gaba transporter heterogeneity: Pharmacology and cellular localization [J].
Borden, LA .
NEUROCHEMISTRY INTERNATIONAL, 1996, 29 (04) :335-356
[4]   Molecular effectors of multiple cell death pathways initiated by photodynamic therapy [J].
Buytaert, Esther ;
Dewaele, Michael ;
Agostinis, Patrizia .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2007, 1776 (01) :86-107
[5]   γ-Aminobutyric acid (A) receptor agonists accelerate cutaneous barrier recovery and prevent epidermal hyperplasia induced by barrier disruption [J].
Denda, M ;
Inoue, K ;
Inomata, S ;
Denda, S .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2002, 119 (05) :1041-1047
[6]   Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo [J].
Dirschka, T. ;
Radny, P. ;
Dominicus, R. ;
Mensing, H. ;
Bruening, H. ;
Jenne, L. ;
Karl, L. ;
Sebastian, M. ;
Oster-Schmidt, C. ;
Kloevekorn, W. ;
Reinhold, U. ;
Tanner, M. ;
Groene, D. ;
Deichmann, M. ;
Simon, M. ;
Huebinger, F. ;
Hofbauer, G. ;
Kraehn-Senftleben, G. ;
Borrosch, F. ;
Reich, K. ;
Berking, C. ;
Wolf, P. ;
Lehmann, P. ;
Moers-Carpi, M. ;
Hoenigsmann, H. ;
Wernicke-Panten, K. ;
Helwig, C. ;
Foguet, M. ;
Schmitz, B. ;
Luebbert, H. ;
Szeimies, R. -M. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (01) :137-146
[7]   PHOTODYNAMIC THERAPY [J].
DOUGHERTY, TJ ;
MARCUS, SL .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (10) :1734-1742
[8]  
DUDECK KL, 1987, J BIOL CHEM, V262, P12565
[9]   PORPHYRIN METABOLISM IN SOME MALIGNANT DISEASES [J].
ELSHARABASY, MMH ;
ELWASEEF, AM ;
HAFEZ, MM ;
SALIM, SA .
BRITISH JOURNAL OF CANCER, 1992, 65 (03) :409-412
[10]  
Ericson Marica B, 2008, Ther Clin Risk Manag, V4, P1